BYM338

Phase 2Small molecule

BYM338 is one of 110 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Weight LossActive, not recruiting

Type 2 DiabetesActive, not recruiting

Inclusion Body MyositisActive, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Weight LossPhase 2

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Inclusion Body MyositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

55 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

BYM338

Novartis

Phase 2

1 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Inclusion Body Myositis2 trials

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Completed· Novartis logo

Novartis·Phase 2·NCT01423110·14 enrolled

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Completed· Novartis logo

Novartis·Phase 2/3·NCT02250443·10 enrolled

Mechanically Ventilated Patients1 trial

Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients

Withdrawn· Novartis logo

Novartis·Phase 2·NCT01868685

Weight loss1 trial

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

Completed· Novartis logo

Novartis·Phase 2·NCT01433263·57 enrolled

Type 2 Diabetes1 trial

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Completed· Novartis logo

Novartis·Phase 2·NCT03005288·78 enrolled

Chronic Obstructive Pulmonary Disease1 trial

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

Completed· Novartis logo

Novartis·Phase 2·NCT01669174·67 enrolled

1 more indication

Adult1 trial

A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

Completed· Novartis logo

Novartis·Phase 2·NCT01601600·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BYM338. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BYM338 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BYM338. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

BYM338

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Inclusion Body Myositis2 trials

Mechanically Ventilated Patients1 trial

Weight loss1 trial

Type 2 Diabetes1 trial

Chronic Obstructive Pulmonary Disease1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News